Mtor - mechanistic target of rapamycin kinase Gene

中文名称：雷帕霉素激酶的机制靶点

种属: Rattus norvegicus

同用名: Frap1; RAFT1

基因 ID: 56718 | 基因类型: protein coding

关于 Mtor

Primary_assembly 5: 158,884,804-158,994,311 forward strand.mRatBN7.2:CM026978.1

This gene has 3 transcripts (splice variants), 217 orthologues, 5 paralogues and is associated with 102 phenotypes. Biased expression in Kidney (RPKM 158.6), Heart (RPKM 127.5) and 9 other tissues.

功能概要

该基因编码的蛋白可启动多种功能，包括蛋白激酶结合活性；蛋白丝氨酸/苏氨酸激酶活性；和翻译调节活动。参与多个过程，包括细胞群增殖的正向调节；调节细胞蛋白质代谢过程；和肌肉适应的调节。在细胞投射组织的上游或内部起作用，并对细胞大小进行负调节。位于细胞质和细胞核中。 TORC1 复合体的一部分。在谷氨酸能突触和突触后细胞质中活跃。与树突和神经细胞体共定位。用于研究多种疾病，包括动脉疾病（多种）；脑部疾病（多种）；新月体性肾小球肾炎;肾功能衰竭（多发）；和肌肉萎缩。多种疾病的生物标志物，包括大脑中动脉梗塞；肥胖; 2型糖尿病；输尿管梗阻；和血管性痴呆。该基因的人类直系同源物与常染色体显性多囊肾病有关；肾血管平滑肌脂肪瘤;肺部疾病（多发）；前列腺癌;和 2 型糖尿病。与人 mTOR 同源（雷帕霉素激酶的机制靶标）。 [由基因组资源联盟提供，2022 年 4 月]

Enables several functions, including protein kinase binding activity; protein serine/threonine kinase activity; and translation regulator activity. Involved in several processes, including positive regulation of cell population proliferation; regulation of cellular protein metabolic process; and regulation of muscle adaptation. Acts upstream of or within cell projection organization and negative regulation of cell size. Located in cytosol and nucleus. Part of TORC1 complex. Is active in glutamatergic synapse and postsynaptic cytosol. Colocalizes with dendrite and neuronal cell body. Used to study several diseases, including artery disease (multiple); brain disease (multiple); crescentic glomerulonephritis; kidney failure (multiple); and muscular atrophy. Biomarker of several diseases, including middle cerebral artery infarction; obesity; type 2 diabetes mellitus; ureteral obstruction; and vascular dementia. Human ortholog(s) of this gene implicated in autosomal dominant polycystic kidney disease; kidney angiomyolipoma; lung disease (multiple); prostate cancer; and type 2 diabetes mellitus. Orthologous to human mTOR (mechanistic target of rapamycin kinase). [provided by Alliance of Genome Resources, Apr 2022]

Mtor 基因产物(1)

mRNA	Protein	Name
NM_019906.2	NP_063971.1	serine/threonine-protein kinase mTOR

基因本体论

分子功能
生物过程
细胞组分

分子功能 GO 注释	逻辑证据	参考文献	来源
enables protein binding	IPI IPI: 通过物理相互作用推断	15525761	RGD
enables protein domain specific binding	IPI IPI: 通过物理相互作用推断	11853878	RGD
enables protein kinase binding	IPI IPI: 通过物理相互作用推断	24583056	RGD
enables protein serine/threonine kinase activity	IDA IDA: 通过直接分析推断	17142137	RGD
enables protein serine/threonine kinase activity	IMP IMP: 通过突变表型推断	15388509	RGD

生物过程 GO 注释	逻辑证据	参考文献	来源
acts upstream of or within cell projection organization	IGI IGI: 通过遗传相互作用推断	16286931	RGD
involved in long-term memory	IMP IMP: 通过突变表型推断	24076274	RGD
involved in mRNA stabilization	IMP IMP: 通过突变表型推断	21073857	RGD
involved in maternal process involved in female pregnancy	IDA IDA: 通过直接分析推断	19589861	RGD
involved in negative regulation of autophagy	IMP IMP: 通过突变表型推断	24725502	RGD
acts upstream of or within negative regulation of cell size	IMP IMP: 通过突变表型推断	16286931	RGD
involved in negative regulation of cholangiocyte apoptotic process	IMP IMP: 通过突变表型推断	24498161	RGD
involved in negative regulation of iodide transmembrane transport	IMP IMP: 通过突变表型推断	20392814	RGD
involved in negative regulation of muscle atrophy	IMP IMP: 通过突变表型推断	19260063	RGD
involved in negative regulation of protein phosphorylation	IMP IMP: 通过突变表型推断	21357504	RGD
involved in negative regulation of protein ubiquitination	IMP IMP: 通过突变表型推断	21357504	RGD
involved in positive regulation of cell growth involved in cardiac muscle cell development	IMP IMP: 通过突变表型推断	21318349	RGD
involved in positive regulation of cellular senescence	IMP IMP: 通过突变表型推断	19698731	RGD
involved in positive regulation of cholangiocyte proliferation	IMP IMP: 通过突变表型推断	24498161	RGD
involved in positive regulation of dendritic spine development	IMP IMP: 通过突变表型推断	21683721	RGD
involved in positive regulation of eating behavior	IMP IMP: 通过突变表型推断	23955309	RGD
involved in positive regulation of endothelial cell proliferation	IMP IMP: 通过突变表型推断	17110594	RGD
involved in positive regulation of epithelial cell apoptotic process	IMP IMP: 通过突变表型推断	21779001	RGD
involved in positive regulation of glial cell proliferation	IMP IMP: 通过突变表型推断	19576187	RGD
involved in positive regulation of granulosa cell proliferation	IMP IMP: 通过突变表型推断	22383759	RGD
involved in positive regulation of neurogenesis	IMP IMP: 通过突变表型推断	19474323	RGD
involved in positive regulation of neuron apoptotic process	IMP IMP: 通过突变表型推断	19474323	RGD
involved in positive regulation of neuron maturation	IMP IMP: 通过突变表型推断	24118019	RGD
involved in positive regulation of neuron projection development	IMP IMP: 通过突变表型推断	22705730	RGD
involved in positive regulation of nitric oxide biosynthetic process	IMP IMP: 通过突变表型推断	19576187	RGD
involved in positive regulation of oligodendrocyte differentiation	IMP IMP: 通过突变表型推断	19439614	RGD
involved in positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	IMP IMP: 通过突变表型推断	17110594	RGD
involved in positive regulation of skeletal muscle hypertrophy	IMP IMP: 通过突变表型推断	23470307	RGD
involved in positive regulation of smooth muscle cell proliferation	IMP IMP: 通过突变表型推断	19589861	RGD
involved in positive regulation of translation	IMP IMP: 通过突变表型推断	15525761	RGD
involved in protein autophosphorylation	IMP IMP: 通过突变表型推断	15388509	RGD
involved in protein phosphorylation	IDA IDA: 通过直接分析推断	17142137	RGD
involved in protein phosphorylation	IMP IMP: 通过突变表型推断	17110594	RGD
involved in regulation of brown fat cell differentiation	IMP IMP: 通过突变表型推断	20133456	RGD
involved in regulation of carbohydrate metabolic process	IDA IDA: 通过直接分析推断	17142137	RGD
involved in regulation of carbohydrate metabolic process	IMP IMP: 通过突变表型推断	17142137	RGD
involved in regulation of carbohydrate utilization	IDA IDA: 通过直接分析推断	17142137	RGD
involved in regulation of carbohydrate utilization	IMP IMP: 通过突变表型推断	17142137	RGD
involved in regulation of fatty acid beta-oxidation	IDA IDA: 通过直接分析推断	17142137	RGD
involved in regulation of fatty acid beta-oxidation	IMP IMP: 通过突变表型推断	17142137	RGD
involved in regulation of glycogen biosynthetic process	IDA IDA: 通过直接分析推断	17142137	RGD
involved in regulation of glycogen biosynthetic process	IMP IMP: 通过突变表型推断	17142137	RGD
involved in regulation of response to food	IDA IDA: 通过直接分析推断	16690869	RGD
involved in regulation of response to food	IMP IMP: 通过突变表型推断	16690869	RGD
involved in regulation of translation at synapse, modulating synaptic transmission	EXP EXP: 通过实验结果推断	15525761	RGD
involved in regulation of translation at synapse, modulating synaptic transmission	IDA IDA: 通过直接分析推断	15525761	RGD
involved in regulation of translation at synapse, modulating synaptic transmission	IEP IEP: 通过表达模式推断	15525761	RGD
involved in regulation of translation at synapse, modulating synaptic transmission	IMP IMP: 通过突变表型推断	15525761	RGD
involved in response to activity	IEP IEP: 通过表达模式推断	28536139	RGD
involved in response to cocaine	IMP IMP: 通过突变表型推断	20977929	RGD
involved in social behavior	IMP IMP: 通过突变表型推断	23027611	RGD
involved in spinal cord development	IDA IDA: 通过直接分析推断	23681769	RGD
involved in visual learning	IMP IMP: 通过突变表型推断	20599569	RGD

细胞组分 GO 注释	逻辑证据	参考文献	来源
part of TORC1 complex	IDA IDA: 通过直接分析推断	17110594	RGD
located in dendrite	IDA IDA: 通过直接分析推断	15525761	RGD
is active in glutamatergic synapse	IDA IDA: 通过直接分析推断	11756682	RGD
located in neuronal cell body	IDA IDA: 通过直接分析推断	15525761	RGD
is active in postsynaptic cytosol	IDA IDA: 通过直接分析推断	11756682	RGD
part of protein-containing complex	IDA IDA: 通过直接分析推断	7822316	RGD

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Mtor 蛋白结构

TEL1

HEAT

0
400
800
1200
1600
2000
2400
2549 a.a.

蛋白主名

其他名称

serine/threonine-protein kinase mTOR

FK506 binding protein 12-rapamycin associated protein 1	FK506-binding protein 12-rapamycin complex-associated protein 1
FKBP12-rapamycin complex-associated protein	RAPT1
mammalian target of rapamycin	mechanistic target of rapamycin (serine/threonine kinase)
rapamycin and FKBP12 target-1 protein	rapamycin target protein 1

相关产品

Approval

生物活性分子 (9)

目录号	产品名	作用方式	纯度	是否罕见病
HY-10219	Rapamycin	Inhibitor	99.94%	是
HY-10218	Everolimus	Inhibitor	99.85%	是
HY-50910	Temsirolimus	Inhibitor	99.56%	是
HY-N0486	L-Leucine	Activator	99.79%	否
HY-N0281	Daphnetin	Inhibitor	99.86%	否
HY-B0766	Bicyclol		99.91%	否
HY-B1232A	Metyrapone Tartrate	Modulator	/	否
HY-B0725A	Doxepin		/	否
HY-10218R	Everolimus (Standard)	Inhibitor	/	否

Clinical Phase

生物活性分子 (30)

目录号	产品名	作用方式	纯度	Phase
HY-10219G	Rapamycin (GMP)	Inhibitor	/	Phase 4
HY-50673	Dactolisib	Inhibitor	99.94%	Phase 3
HY-10681	Gedatolisib	Inhibitor	99.68%	Phase 3
HY-15174	Dactolisib Tosylate	Inhibitor	99.87%	Phase 3
HY-50908	Ridaforolimus	Inhibitor	99.28%	Phase 3
HY-13328	Sapanisertib	Inhibitor	99.66%	Phase 2
HY-139609	Camonsertib	Inhibitor	99.75%	Phase 2
HY-N0112	Dihydromyricetin	Inhibitor	98.10%	Phase 2
HY-114384	NV-5138	Activator	≥98.0%	Phase 2
HY-15247	Vistusertib	Inhibitor	98.91%	Phase 2
HY-12513	Samotolisib	Inhibitor	99.27%	Phase 2
HY-15177	PF-04691502	Inhibitor	99.91%	Phase 2
HY-114384B	NV-5138 hydrochloride	Activator	≥98.0%	Phase 2
HY-13246	Apitolisib	Inhibitor	99.29%	Phase 2
HY-16962	CC-115	Inhibitor	99.82%	Phase 2
HY-15900	Voxtalisib	Inhibitor	98.81%	Phase 2
HY-13334A	BGT226	Inhibitor	99.51%	Phase 2
HY-16956	Onatasertib	Inhibitor	99.13%	Phase 2
HY-12868	Bimiralisib	Inhibitor	99.80%	Phase 2
HY-13334	BGT226 maleate	Inhibitor	99.87%	Phase 2
HY-16962A	CC-115 hydrochloride	Inhibitor	98.03%	Phase 2
HY-13691	MKC-1	Inhibitor	99.23%	Phase 2
HY-10422	AZD-8055	Inhibitor	99.60%	Phase 1
HY-132168	RMC-5552	Inhibitor	98.10%	Phase 1
HY-10297	Omipalisib	Inhibitor	99.93%	Phase 1
HY-12036	GSK1059615	Inhibitor	≥99.0%	Phase 1
HY-10423	OSI-027	Inhibitor	99.40%	Phase 1
HY-16585	VS-5584	Inhibitor	99.14%	Phase 1
HY-15248	GDC-0349	Inhibitor	98.02%	Phase 1
HY-14581	Palomid 529	Inhibitor	99.47%	Phase 1

Pre-clinical Phase

生物活性分子 (210)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-B0795	MHY1485	Activator	99.86%	否
HY-13003	Torin 1	Inhibitor	99.08%	否
HY-N0109	Salidroside	Activator	99.79%	否
HY-13002	Torin 2	Inhibitor	99.65%	否
HY-U00434	3BDO	Activator	99.93%	否
HY-10115	PI-103	Inhibitor	98.93%	否
HY-122022	JR-AB2-011	Inhibitor	99.16%	否
HY-111373	RapaLink-1	Inhibitor	99.27%	否
HY-10474	Torkinib	Inhibitor	98.37%	否
HY-100542	D-α-Hydroxyglutaric acid disodium	Inhibitor	≥98.0%	否
HY-124719	hSMG-1 inhibitor 11j	Inhibitor	99.82%	否
HY-N0189	Aloe emodin	Inhibitor	98.32%	否
HY-124798	Rheb inhibitor NR1	Inhibitor	99.46%	否
HY-N0047	Polyphyllin I	Inhibitor	99.89%	否
HY-116522	AR420626		98.29%	否
HY-N0787	Cryptochlorogenic acid	Inhibitor	99.87%	否
HY-50710	KU-0063794	Inhibitor	99.55%	否
HY-W012722	4-Methyl-2-oxopentanoic acid	Inhibitor	99.51%	否
HY-124760	hSMG-1 inhibitor 11e	Inhibitor	99.81%	否
HY-155747	FDW028	Inhibitor	99.51%	否
HY-19962	Paxalisib	Inhibitor	99.63%	是
HY-134904	RMC-6272	Inhibitor	95.54%	否
HY-10044	WYE-132	Inhibitor	99.90%	否
HY-N0486S9	L-Leucine-d3	Activator	≥98.0%	否
HY-N0486S1	L-Leucine-13C	Activator	99.4%	否
HY-N6626	Pyraclostrobin		99.91%	否
HY-10372	PP121	Inhibitor	98.67%	否
HY-18353	mTOR inhibitor-3	Inhibitor	99.09%	否
HY-13431	KU-0060648	Inhibitor	99.62%	否
HY-10683	PKI-402	Inhibitor	98.43%	否
HY-115449	Chromeceptin	p53 Inhibitor	99.91%	否
HY-146751	PI3K/Akt/mTOR-IN-2	Inhibitor	99.86%	否
HY-W016412	Coenzyme Q0	Inhibitor	99.88%	否
HY-100222	CZ415	Inhibitor	98.39%	否
HY-12763	GNE-317	Inhibitor	99.14%	否
HY-N6996	Methyl Eugenol	Inhibitor	99.79%	否
HY-W592871	10-Hydroxy-2-decenoic acid		99.99%	否
HY-107365	PQR530	Inhibitor	99.98%	否
HY-10115A	PI-103 Hydrochloride	Inhibitor	98.00%	否
HY-10219S	Rapamycin-d3	Inhibitor	95.48%	否
HY-N0107	Cyclovirobuxine D	Inhibitor	≥98.0%	否
HY-N0656A	(+)-Usnic acid	Inhibitor	99.63%	否
HY-12034	WYE-354	Inhibitor	98.04%	否
HY-N2217	Rotundic acid	Inhibitor	99.41%	否
HY-15521	ETP-46464	Inhibitor	99.55%	否
HY-156671	RMC-4998	Inhibitor	96.33%	否
HY-15272	WAY-600	Inhibitor	99.75%	否
HY-N0486S3	L-Leucine-15N	Activator	≥98.0%	否
HY-100026	PQR620	Inhibitor	98.01%	否
HY-137175	TMBIM6 antagonist-1	Antagonist	99.60%	否
HY-N0486S	L-Leucine-d10	Activator	≥98.0%	否
HY-N0486S8	L-Leucine-13C6,15N	Activator	99.90%	否
HY-10811	GNE-493	Inhibitor	99.81%	否
HY-114414	HDACs/mTOR Inhibitor 1	Inhibitor	99.01%	否
HY-109046	Tulrampator		98.92%	否
HY-11080	PKI-179	Inhibitor	≥98.0%	否
HY-W058849	MT 63-78	Inhibitor	98.50%	否
HY-N6843	Arnicolide D	Inhibitor	99.20%	否
HY-118717	mTOR inhibitor WYE-28	Inhibitor	99.75%	否
HY-100470	NSC781406	Inhibitor	99.97%	否
HY-100398	PF-04979064	Inhibitor	99.54%	否
HY-110109	ETP-45658	Inhibitor	98.97%	否
HY-N6950	Hederacolchiside A1	Modulator	99.69%	否
HY-11042	GNE-477	Inhibitor	98.75%	否
HY-111508	PI3K/mTOR Inhibitor-2	Inhibitor	99.10%	否
HY-128333	PI3K/mTOR Inhibitor-4	Inhibitor	97.00%	否
HY-N1050	Zederone	Inhibitor	99.61%	否
HY-15271	WYE-687	Inhibitor	98.05%	否
HY-13806	XL388	Inhibitor	99.74%	否
HY-112914	mTOR inhibitor-1	Inhibitor	98.82%	否
HY-126077	MTI-31	Inhibitor	99.98%	否
HY-12652	AZD3147	Inhibitor	99.93%	否
HY-124582	NEO214	Activator	≥98.0%	否
HY-N9942	Physalin A	Inhibitor	99.22%	否
HY-131344	mTOR inhibitor-8	Inhibitor	97.08%	否
HY-136660	PQR626	Inhibitor	98.05%	否
HY-137315	TML-6	Inhibitor	99.01%	否
HY-163198	ASCT2-IN-1	Inhibitor	98.21%	否
HY-N0486S2	L-Leucine-13C6	Activator	≥98.0%	否
HY-122665	HTH-01-091	Inhibitor	98.64%	否
HY-163199	ASCT2-IN-2	Inhibitor	99.10%	否
HY-134903	(32-Carbonyl)-RMC-5552	Inhibitor	95.41%	否
HY-151622	PI3K/mTOR Inhibitor-11	Inhibitor	98.74%	否
HY-124036	DS-7423	Inhibitor	99.75%	否
HY-107363	FT-1518	Inhibitor	98.14%	否
HY-114267	Cbz-B3A	Inhibitor	≥98.0%	否
HY-153120A	PI3K/mTOR Inhibitor-13 sodium	Inhibitor	98.13%	否
HY-162382	KTC1101	Inhibitor	98.09%	否
HY-145931	CC214-2	Inhibitor	98.41%	否
HY-N2590	Lupenone		99.74%	否
HY-W348485	WRX606	Inhibitor	95.65%	否
HY-159480	AD1058	Inhibitor	/	否
HY-11080A	PKI-179 hydrochloride	Inhibitor	99.66%	否
HY-141805	MHY-1685	Inhibitor	99.97%	否
HY-125927	8-Aminoadenosine	Inhibitor	99.94%	否
HY-111065	OXA-01	Inhibitor	/	否
HY-101776A	Desmethyl-VS-5584 hydrochloride	Inhibitor	98.63%	否
HY-10219GL	Rapamycin (GMP Like)	Inhibitor	98.8%	否
HY-N3628	Coronarin A	Inhibitor	≥98.0%	否
HY-155066	FD274	Inhibitor	/	否
HY-B1787	Sulindac sulfone	Inhibitor	98.08%	否
HY-109633	PI3K-IN-18	Inhibitor	≥99.0%	否
HY-122665A	HTH-01-091 TFA	Inhibitor	99.48%	否
HY-N4315	Pomiferin	Inhibitor	98.98%	否
HY-157169	IBL-302	Inhibitor	98.21%	否
HY-15271A	WYE-687 dihydrochloride	Inhibitor	≥98.0%	否
HY-N0486S12	L-Leucine-d2	Activator	≥99.0%	否
HY-143510	RMC-4627		99.20%	否
HY-N5136	25(R,S)-Ruscogenin	Inhibitor	98.59%	否
HY-147284	PI3K-IN-37	Inhibitor	≥99.0%	否
HY-10620	PI3K-IN-22	Inhibitor	99.50%	否
HY-U00326	PI3Kα/mTOR-IN-1	Inhibitor	99.30%	否
HY-10812	GNE-490	Inhibitor	96.29%	否
HY-151137	HSP90/mTOR-IN-1	Inhibitor	/	否
HY-10218S	Everolimus-d4	Inhibitor	97.88%	否
HY-119665	Asteltoxin	Inhibitor	/	否
HY-139832	MCX 28	Inhibitor	/	否
HY-161509	PT-88	Inhibitor	/	否
HY-128027	eCF309	Inhibitor	98.2%	否
HY-147913	PI3K/Akt/mTOR-IN-3	Inhibitor	/	否
HY-144687	ATM Inhibitor-4	Inhibitor	/	否
HY-146016	PI3K/mTOR Inhibitor-5	Inhibitor	/	否
HY-N0486S10	L-Leucine-18O2	Activator	/	否
HY-154910	CC214-1	Inhibitor	/	否
HY-N0486S6	L-Leucine-2-13C,15N	Activator	/	否
HY-163511	PI3K/Akt/mTOR-IN-4	Inhibitor	/	否
HY-161856	Antifungal agent 106	Inhibitor	/	否
HY-150061	NVP-BBD130	Inhibitor	/	否
HY-169100	Antiproliferative agent-57		/	否
HY-155376	mTOR inhibitor-14	Inhibitor	/	否
HY-RS08811	Mtor Mouse Pre-designed siRNA Set A	Inhibitor	/	否
HY-N10754	Aschantin	Inhibitor	/	否
HY-160548	mTOR inhibitor-18	Inhibitor	/	否
HY-N2517	Dihydroevocarpine	Inhibitor	99.62%	否
HY-15281	QL-IX-55	Inhibitor	/	否
HY-RS08812	Mtor Rat Pre-designed siRNA Set A	Inhibitor	/	否
HY-15901	LGB321	Inhibitor	/	否
HY-141476	PI3K/mTOR Inhibitor-3	Inhibitor	/	否
HY-162147	Nur77 modulator 3	Inhibitor	99.01%	否
HY-N0486S13	L-Leucine-15N,d10		/	否
HY-13847	GNE-555	Inhibitor	/	否
HY-162143	SKI-349	Inhibitor	99.58%	否
HY-101776	Desmethyl-VS-5584	Inhibitor	/	否
HY-169022	4-FPBUA	Inhibitor	/	否
HY-141701	mTOR/HDAC-IN-1	Inhibitor	/	否
HY-118712	mTOR inhibitor WYE-23	Inhibitor	/	否
HY-113038	D-α-Hydroxyglutaric acid	Inhibitor	/	否
HY-137315S	TML-6-d3		/	否
HY-N0486S4	L-Leucine-d7	Activator	/	否
HY-154958	mTOR inhibitor-12	Inhibitor	/	否
HY-18953	mTOR inhibitor-23	Inhibitor	/	否
HY-P5984	Thioether-cyclized helix B peptide, CHBP	Inhibitor	/	否
HY-147285	PI3K/mTOR Inhibitor-9	Inhibitor	/	否
HY-15269	PP30	Inhibitor	/	否
HY-118704	P-2281	Inhibitor	99.81%	否
HY-147614	PI3K/mTOR Inhibitor-7	Inhibitor	/	否
HY-154957	mTOR inhibitor-11	Inhibitor	/	否
HY-N0486S7	L-Leucine-1-13C,15N	Activator	≥98.0%	否
HY-P1823	C-Reactive Protein (CRP) (174-185)	Modulator	99.83%	否
HY-N0486S11	L-Leucine-d1	Activator	/	否
HY-137996	Dehydrovomifoliol	Inhibitor	/	否
HY-115869	RMC-4529	Inhibitor	/	否
HY-127067	Yuanhuadin	Inhibitor	/	否
HY-156027	SIRT6-IN-3	Inhibitor	/	否
HY-125535	OSU-53	Inhibitor	/	否
HY-146200	PI3K/mTOR Inhibitor-8	Inhibitor	/	否
HY-151915	ATR-IN-20	Inhibitor	/	否
HY-159517	PI3K/Akt/mTOR-IN-5	Inhibitor	/	否
HY-P10323	T7 Peptide	Inhibitor	/	否
HY-N1244	Sarmentosin	Inhibitor	/	否
HY-159577	Nic-15	Modulator	/	否
HY-147613	PI3K/mTOR Inhibitor-6	Inhibitor	/	否
HY-156432	ALK-IN-26	Inhibitor	99.87%	否
HY-N6626R	Pyraclostrobin (Standard)		/	否
HY-156445	PI3K/mTOR Inhibitor-14	Inhibitor	/	否
HY-147966	HDAC-IN-43	Inhibitor	/	否
HY-144295	PI3Kα-IN-5	Inhibitor	/	否
HY-144449	mTOR/HDAC6-IN-1	Inhibitor	/	否
HY-121726	3HOI-BA-01	Inhibitor	/	否
HY-144686	ATM Inhibitor-3	Inhibitor	/	否
HY-152238	PI3K/mTOR Inhibitor-12	Inhibitor	/	否
HY-P5984A	Thioether-cyclized helix B peptide, CHBP TFA	Inhibitor	/	否
HY-155721	22-(4′-py)-JA	Inhibitor	/	否
HY-N1338	Royleanone	Inhibitor	/	否
HY-N0486S5	L-Leucine-2-13C	Activator	/	否
HY-10116	PI-540	Inhibitor	/	否
HY-15268	PP487	Inhibitor	/	否
HY-161857	Akt/mTOR-IN-1	Inhibitor	/	否
HY-RS08810	MTOR Human Pre-designed siRNA Set A	Inhibitor	/	否
HY-15901A	LGB321 monohydrochloride	Inhibitor	/	否
HY-123849	SN32976	Inhibitor	/	否
HY-N12124	Monascuspiloin	Inhibitor	/	否
HY-153120	PI3K/mTOR Inhibitor-13	Inhibitor	/	否
HY-169121	DA-143	Inhibitor	/	否
HY-N0109R	Salidroside (Standard)	Activator	/	否
HY-162023	mTOR inhibitor-10	Inhibitor	/	否
HY-N13176	Stellettin B	Inhibitor	/	否
HY-164385	NSC126405	Inhibitor	/	否
HY-155211	mTOR inhibitor-13	Inhibitor	/	否
HY-164384	DFX117	Inhibitor	/	否
HY-162024	mTOR inhibitor-16	Inhibitor	/	否
HY-116191	WJD008	Inhibitor	/	否
HY-164662	mTOR inhibitor-24	Inhibitor	/	否
HY-155475	mTORC1-IN-2	Inhibitor	/	否
HY-117923	PF-06465603	Inhibitor	/	否
HY-W779800	D-α-Hydroxyglutaric acid-13C5 disodium	Inhibitor	/	否
HY-162025	mTOR inhibitor-17	Inhibitor	/	否
HY-W654330	Pyraclostrobin-d6		/	否
HY-112602	PI3K/mTOR Inhibitor-1	Inhibitor	/	否
HY-111370	mTOR inhibitor-2	Inhibitor	/	否

直系同源

种属	基因名	来源	基因 ID
Homo sapiens	Mtor	NCBI	NCBI:2475

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.